CNS Drugs · 2024 · 13 citations · 166 references
MedicineInfectious DiseasesPharmacologyMolecular VirologyNeuroinfectious DiseasesVirologyAntiviral AgentsAntiviral TherapyBlood-brain Barrier PenetrationCentral Nervous System InfectionsEncephalitisViral InfectionsAntiviral TherapeuticsAntiviral TreatmentBlood - Brain Barrier InvasionBlood-brain Barrier InvasionBlood-brain Barrier PermeabilityCentral Nervous System Infection TreatmentNeurotropic Viral InfectionNeurotropic Viral Pathogenesis
Neurotropic viruses may cause meningitis, myelitis, encephalitis, or meningoencephalitis. These inflammatory conditions of the central nervous system (CNS) may have serious and devastating consequences if not treated adequately. In this review, we first summarize how neurotropic viruses can enter the CNS by (1) crossing the blood-brain barrier or blood-cerebrospinal fluid barrier; (2) invading the nose via the olfactory route; or (3) invading the peripheral nervous system. Neurotropic viruses may then enter the intracellular space of brain cells via endocytosis and/or membrane fusion. Antiviral drugs are currently used for different viral CNS infections, even though their use and dosing regimens within the CNS, with the exception of acyclovir, are minimally supported by clinical evidence. We therefore provide considerations to optimize drug treatment(s) for these neurotropic viruses. Antiviral drugs should cross the blood-brain barrier/blood cerebrospinal fluid barrier and pass the brain cellular membrane to inhibit these viruses inside the brain cells. Some antiviral drugs may also require intracellular conversion into their active metabolite(s). This illustrates the need to better understand these mechanisms because these processes dictate drug exposure within the CNS that ultimately determine the success of antiviral drugs for CNS infections. Finally, we discuss mathematical model-based approaches for optimizing antiviral treatments. Thereby emphasizing the potential of CNS physiologically based pharmacokinetic models because direct measurement of brain intracellular exposure in living humans faces ethical restrictions. Existing physiologically based pharmacokinetic models combined with in vitro pharmacokinetic/pharmacodynamic information can be used to predict drug exposure and evaluate efficacy of antiviral drugs within the CNS, to ultimately optimize the treatments of CNS viral infections.
166
Inge Hamming, Wim Timens, MLC Bulthuis et al. · The Journal of Pathology · 2004 · 5.9K citations · Full text
Veterinary Medicine, Infectious Diseases, Molecular Biology +11
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series
Jakob Matschke, Marc Lütgehetmann, Christian Hagel et al. · The Lancet Neurology · 2020 · 1.4K citations · Full text